IFIH1 and dermatomyositis: This study aimed to explore the differences in the clinical manifestations and long-term mortality of anti-MDA5+ DM patients across age groups.<h4>Methods</h4>We included 318 newly diagnosed anti-MDA5+ DM patients, recruited from June 2018 to January 2024.